Advances in diagnostic tools have dramatically expanded in the past year, making available to patients several blood tests to help diagnose Alzheimer’s disease. C₂N is developing a platform that will enable global access to its next generation PrectivityAD2™ blood test and other precision medicine tools. These tests enable healthcare providers to give patients an early and accurate diagnosis.
Dr. Mark Monane is a geriatrician and senior medical advisor to C₂N who has spent over three decades working at the intersection of aging, evidence, and real-world decision-making. Trained in geriatric medicine and clinical effectiveness, he has led and advised across the full ecosystem that shapes care for older adults – clinical practice, outcomes research, payer policy, diagnostics innovation, and the investor community. He previously served as Chief Medical Officer at CardioDx and as Managing Director of biotech equity research at Needham & Company, and earlier held a senior medical policy role at Merck-Medco. Dr. Monane holds an MD (NYU), an MSHPM (Harvard), and an MBA (Columbia), and is a Fellow of the American Geriatrics Society and the American Heart Association.
“Tomorrow’s Breakthroughs Today” features world-class scientists discussing the path toward new, cutting-edge treatments for Alzheimer’s disease. Now in its fifth season, this lecture series invites three top investigators to share the latest breaking updates on their research with moderator Dr. Howard Fillit, Co-Founder and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF). Founded in 1998 by Leonard A. and Ronald S. Lauder, the ADDF is dedicated to rapidly accelerating the development of novel therapeutics and biomarkers to prevent, treat, and cure Alzheimer’s disease and related dementias.
Presented by the Alzheimer’s Drug Discovery Foundation in partnership with Heidi and Tom McWilliams
